title: Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.
abstract: OBJECTIVE
  To evaluate the short-term efficacy of intravitreal adalimumab (IVA) for the treatment of eyes with active noninfectious uveitis.
  
  
  METHODS
  Consecutive eyes with active noninfectious uveitis were injected with IVA at 0, 2, then every 4 weeks for total of 26 weeks.
  
  
  RESULTS
  Six out of 7 patients (12 of 13 eyes) completed 26 weeks of treatment. One patient (1 eye) failed treatment. Seven out of 12 eyes had improvement of ≥2 ETDRS lines. Three out of three eyes had resolution of anterior chamber cells. And 9 of 10 eyes with vitreous haze had zero haze at 26 weeks. Five out of 8 eyes with macular edema had complete resolution. Median fluorescein angiography score improved from 14 to 4 on last follow-up.
  
  
  CONCLUSIONS
  IVA was effective in controlling the inflammation, decreasing the macular edema, and improving the best corrected visual acuity in the majority of eyes in this series.
authors.affiliation: a Department of Ophthalmology , American University of Beirut Medical Center , Beirut , Lebanon and.
authors.forename: Rola N
authors.initials: RN
authors.lastname: Hamam
authors.affiliation: a Department of Ophthalmology , American University of Beirut Medical Center , Beirut , Lebanon and.
authors.forename: Anita W
authors.initials: AW
authors.lastname: Barikian
authors.affiliation: a Department of Ophthalmology , American University of Beirut Medical Center , Beirut , Lebanon and.
authors.forename: Rafic S
authors.initials: RS
authors.lastname: Antonios
authors.affiliation: a Department of Ophthalmology , American University of Beirut Medical Center , Beirut , Lebanon and.
authors.forename: Marwan R
authors.initials: MR
authors.lastname: Abdulaal
authors.affiliation: a Department of Ophthalmology , American University of Beirut Medical Center , Beirut , Lebanon and.
authors.forename: Ramzi M
authors.initials: RM
authors.lastname: Alameddine
authors.affiliation: b Department of Ophthalmology , Université de Montreal , Montreal , Canada.
authors.forename: Georges
authors.initials: G
authors.lastname: El Mollayess
authors.affiliation: a Department of Ophthalmology , American University of Beirut Medical Center , Beirut , Lebanon and.
authors.forename: Ahmad M
authors.initials: AM
authors.lastname: Mansour
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000867:Anterior Chamber / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015817:Eye Infections / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body / Q000187:drug effects; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
keywords: Adalimumab; intravitreal adalimumab; noninfectious uveitis; uveitis treatment